Veru (NASDAQ:VERU) Raised to “Buy” at Zacks Investment Research

Zacks Investment Research upgraded shares of Veru (NASDAQ:VERUGet Rating) from a hold rating to a buy rating in a report issued on Friday morning, Zacks.com reports. Zacks Investment Research currently has $16.00 target price on the stock.

According to Zacks, “Veru Inc. engages in the development, manufacture and marketing of consumer health care products. It focuses on producing FC2 female condom which provides dual protection against unintended pregnancy and sexually transmitted infections. Veru Inc., formerly known as The Female Health Company, is headquartered in Miami, FL. “

Other analysts have also issued research reports about the stock. TheStreet lowered shares of Veru from a c- rating to a d rating in a research note on Thursday, February 10th. Oppenheimer lifted their price objective on shares of Veru from $25.00 to $36.00 and gave the company an outperform rating in a research note on Tuesday, April 12th. Finally, HC Wainwright lifted their price objective on shares of Veru from $21.00 to $24.00 and gave the company a buy rating in a research note on Tuesday, April 12th. Four research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of Buy and a consensus target price of $25.33.

Veru stock opened at $14.95 on Friday. Veru has a 52-week low of $4.34 and a 52-week high of $17.50. The firm has a 50 day moving average price of $6.14 and a two-hundred day moving average price of $6.71. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of -74.75 and a beta of 0.49.

Veru (NASDAQ:VERUGet Rating) last released its quarterly earnings results on Wednesday, February 9th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03. Veru had a negative net margin of 26.68% and a negative return on equity of 10.62%. The firm had revenue of $14.14 million during the quarter, compared to analyst estimates of $17.24 million. During the same quarter last year, the business earned ($0.02) EPS. Equities research analysts expect that Veru will post -0.32 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of VERU. PNC Financial Services Group Inc. increased its stake in Veru by 833.3% during the 3rd quarter. PNC Financial Services Group Inc. now owns 5,600 shares of the company’s stock valued at $49,000 after purchasing an additional 5,000 shares in the last quarter. Ensign Peak Advisors Inc bought a new stake in Veru during the 4th quarter valued at $51,000. Josh Arnold Investment Consultant LLC bought a new stake in Veru during the 4th quarter valued at $59,000. Bridgefront Capital LLC bought a new stake in Veru during the 4th quarter valued at $63,000. Finally, Qube Research & Technologies Ltd bought a new stake in Veru during the 4th quarter valued at $73,000. 30.42% of the stock is owned by institutional investors and hedge funds.

Veru Company Profile (Get Rating)

Veru Inc, an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N.

See Also

Get a free copy of the Zacks research report on Veru (VERU)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.